Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HealPACK is a premium line of surgical dressing products and tissue-based regenerative wound care solutions. Developed by Tiger BioSciences (through its subsidiary Tiger Wound Care) following the acquisition of Novo Health Care Service's Encore Surgical HealPACK Solutions in February 2025, the product line is classified as Class I and Class II medical devices. HealPACK consists of a combination of components including porous collagen membranes, high-surface-area collagen powder, silicone composite dressings, and island composite dressings. It is indicated for the management of various wound types, including post-surgical and post-operative wounds, diabetic foot ulcers, pressure ulcers, venous ulcers, and lacerations. The system is physician-prescribed and often integrated with a dedicated mobile application for prescription management and insurance verification.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HealPACK.